|
 |
|
ī̸ġ ǰ ΰ |
۷ι ̿ ѱֺ(ǥ̻ ҿ) ڻ ͷŲ-23(IL-23) ī̸ġʵø(Skyrizi, и Űָ, Risankizumab) Ǵ ġ( ) ʿ ϴ ߵ ǻ Ǽġ 3ڷ ǰǾǰó 㰡 Ҵٰ .
̹ 㰡 ٰŰ UltIMMa-1 UltIMMa-2 ӻ 16 Ǻΰ , ȯ κ(82%, 81%) 1(52) Ŀ Ǽ Ǻΰ 90% ϰ ư(PASI 90), ټ(56%, 60%) ȯڰ Ǽ Ǻΰ ϰ (PASI 100).
д缭б Ǻΰ “ Ǽ ü, , ȸ ɰ ִ ȯ, ȯڿ ġ ̰ ϰ, Ⱓ ġԿ پ ۿ ϰ ȴ” “ī̸ġ 3 ӻ 16 90%̻ ȯ 80% 1 Ŀ ȣ ¸ Ǽȯ ġḦ ο ġ ɼ ”̶ ߴ.
ī̸ġ 뷮 0, 4 150mg ֻ ϰ, Ŀ 12ָ Ѵ. Ե IL-23迭 ʷ 4ȸ ּ Ƚ ްų ڰ ֻ ִ.
ѱֺ к ̻ “ī̸ġ Ǽ ȯڵ ϴ Ǻο ȿ Ⱓ , Ǽ̶ η ġ, ̹ 㰡 Ǽ Ǻ ȿ ϴ Ǽ ȯ ġῡ ߿ ǥ ”̶ “ֺ ī̸ġ 鿪 о μ Ǽ ȯڵ 䱸 ϴ Ʈ Ȯϰ, Ǽ 鿪 Ű ȯ ġ ”̶ ߴ.
ī̸ġ 鿪 Ű ȯ ߰ IL-23 ϴ , IL-23 p19 IL-23 ü ϴ Ѵ.
ī̸ġ 2109 ȯڸ 4 ӻ(UltIMMa-1, UltIMMa-2, IMMvent IMMhance) ġ ȿ ƴ. UltIMMa-1 UltIMMa-2 , 16 ī̸ġ ġ ȯ 75% 90% Ǻ (PASI 90) (placebo 5%, 2%, P<0.001), 100% Ǻ (PASI 100) ȯ 36%, 51% Ÿ(placebo 0%, 2%, P<0.001). ī̸ġ ȯڸ м , 16ֽ 90% Ǻ 100% Ǻ ȯ κ 1 ġ Ÿ(PASI 90 PASI 100 88%, 80%).
1 κ ȯڿ Ǻΰ ǰ, ȿ ȯڰ Բ 6 24ȸ Ǻΰȸ(24th World Congress of Dermatology, WCD) 2 ǥƴ. IMMhance ī̸ġ 2 (ִ 104) ȿ Ͱ õ ̴. 28 Ǻΰ ų(sPGA 0: static Physician Global Assessment 0) Ǻΰ (sPGA 1) ȯڱ ī̸ġ ౺ ٽ ش ī̸ġ 73% 72% 94 Ŀ Ǻ ȿ(sPGA 0, PASI 100) Ÿ. ݸ, ౺ ȯ 7% 4% (p<0.001).
Ǽ 鿪 ̻ ϴ Ǻȯ, Ȳġ, , к μ ȫ Ѵ. 츮 3% ϴ ̸, 150 ȯڰ ִ ˷ ִ. Ư Ǽ ȯڵ , 巯 ȸ ߰ 찡 . ̷ ȸ δ ɸ Ʈ , ȭ ߱ ֱ Ȯϰ ġᰡ ʿϴ.
, ī̸ġ 3 Ϻ Ļ뵿(MHLW) ġ ȿ ǻ Ǽ, Ǽ, ȫ Ǻ Ǽ Ǽ ȯ ġῡ ù 㰡 , 4 ̱ ǰǾ౹(FDA) ȸ(EC) ߵ ǻ Ǽ ȯ ġῡ Ҵ.
ī̸ġ ΰӰ ֺ ϰ ִ ǰ ϳ, ֺ ߰ ۷ι ǸŸ Ѵ.
< ۱ © ʴ >
|